Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis (REMOVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03266302
Recruitment Status : Recruiting
First Posted : August 30, 2017
Last Update Posted : February 27, 2019
Sponsor:
Collaborators:
CytoSorbents, Inc
Thermo Fisher Scientific
Fraunhofer Institute for Interfacial Engineering and Biotechnology
German Federal Ministry of Education and Research
Information provided by (Responsible Party):
Jena University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Infective endocarditis (IE) is associated with high hospital mortality for various reasons; one of them is circulatory failure in patients who undergo cardiac surgery for IE. One discussed reason underlying circulatory failure during surgery is the release of vasodilatatory mediators and cytokines. This study examines the efficacy and safety of a hemoadsorption filter which is approved for the reduction of the concentration of cytokines in the bloodstream.

Condition or disease Intervention/treatment Phase
Infective Endocarditis Device: hemoadsorber for removal of cytokines Not Applicable

Detailed Description:
The investigators assume a common standard deviation of 3.8 points and that a 1.4-point lower SOFA score in the Intervention Group is of clinical relevance.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: two-arm randomized-controlled group sequential (Pocock) design for assessing superiority and safety
Masking: Single (Participant)
Masking Description: Participant will not be informed about group allocation
Primary Purpose: Prevention
Official Title: Revealing Mechanisms and Investigating Efficacy of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis - a Multicentric Randomized Controlled Group Sequential Trial
Actual Study Start Date : January 17, 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : July 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Interventional group
Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery due to infective endocarditis will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
 Device: hemoadsorber for removal of cytokines
Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.
Other Name: CytoSorb(R)
No Intervention: Control group
Participants undergoing cardiac surgery due to infective endocarditis will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. SOFA Score [ Time Frame: 24 hours before until day 9 post-surgery ]
    The investigators will test if mean SOFA scores are different for the experimental and control group.


Secondary Outcome Measures :
  1. Overall mortality rate [ Time Frame: until day 30 post surgery ]
    Overall mortality rate until day 30 post-surgery

  2. Changes in cytokine and cfDNA levels [ Time Frame: 24 hours before, during cardiac surgery and 24 hours after surgery ]
    changes in cytokine and cfDNA levels will be measured at different time points before, during and after surgery in both groups; only for the first 2x25 patients

  3. SOFA subscores [ Time Frame: 24 hours before surgery until day 9 post-surgery ]
    single SOFA subscores will be analyzed

  4. Days on ventilator, vasopressor and renal replacement therapy [ Time Frame: until day 30 post-surgery ]
    Total days on ventilator, vasopressor and renal replacement therapy within 30 days post-surgery will be assessed

  5. incidence of stroke [ Time Frame: until day 30 post-surgery ]
    incidence of stroke within 30 days post-surgery will be assessed

  6. length of ICU and in-hospital stay [ Time Frame: until day 30 post-surgery ]
    total length of ICU and in-hospital stay until day 30 post-surgery


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with infective endocarditis (according to DUKE criteria) undergoing cardiac surgery
  • informed consent
  • age ≥18 years

Exclusion Criteria:

  • EuroScoreII ≤ 3
  • current participation in another interventional Trial
  • pregnancy
  • current immunosuppressive or immunomodulatory therapy (with dosing of glucocorticoids over Cushing threshold)
  • previous participation in the REMOVE study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03266302


Contacts
Layout table for location contacts
Contact: Stephanie Platzer, Dr. +49 3641 ext 9396696 stephanie.platzer@med.uni-jena.de
Contact: Frank M Brunkhorst, Prof. Dr. +49 3641 ext 9323381 Frank.Brunkhorst@med.uni-jena.de

Locations
Layout table for location information
Germany
University Heart Center Bad Krozingen Recruiting
Bad Krozingen, Baden-Württemberg, Germany, D-79189
Contact: Wolfgang Bothe, PD Dr.       wolfgang.bothe@universitaets-herzzentrum.de   
Contact: Friedhelm Beyersdorf, Prof. Dr.       friedhelm.beyersdorf@universitaets-herzzentrum.de   
University Heart Center Freiburg Recruiting
Freiburg, Baden-Württemberg, Germany, D-79106
Contact: Wolfgang Bothe, PD Dr.       wolfgang.bothe@universitaets-herzzentrum.de   
Contact: Friedhelm Beyersdorf, Prof. Dr.       friedhelm.beyersdorf@universitaets-herzzentrum.de   
University Hospital Ulm, Clinics of Heart-, Thoracic and Cardiovascular Surgery Active, not recruiting
Ulm, Baden-Württemberg, Germany, D-89081
University Hospital Cologne, Clinic and Policlinics for Heart and Thoracic Surgery Recruiting
Cologne, North Rhine-Westphalia, Germany, D-50937
Contact: Antje-Christin Deppe, PD Dr.       antje-christin.deppe@uk-koeln.de   
Contact: Carolyn Weber, Dr.       carolyn.weber@uk-koeln.de   
University Hospital Essen, Clinic of Thoracic and Cardiovascular Surgery Recruiting
Essen, North Rhine-Westphalia, Germany, D-45147
Contact: Daniel Wendt, PD Dr.       daniel.wendt@uk-essen.de   
Contact: Matthias Thielmann, Prof. Dr.       matthias.thielmann@uk-essen.de   
Jena University Hospital, Dept. of Cardiac and Thoracic Surgery Recruiting
Jena, Thuringia, Germany, 07747
Contact: Mahmoud Diab, Dr. med.    +49 3641 ext 322978    mahmoud.diab@med.uni-jena.de   
Herz- und Diabeteszentrum NRW, Klinik für Thorax- und Kardiovaskularchirurgie Not yet recruiting
Bad Oeynhausen, Germany, 32545
Contact: René Schramm, Prof. Dr.       rschramm@hdz-nrw.de   
Contact: Sven Helms, Dr.       shelms@hdz-nrw.de   
Herzzentrum Brandenburg, Immanuel Klinikum Bernau Recruiting
Bernau bei Berlin, Germany, 16321
Contact: Georg Fritz, Dr.       g.fritz@immanuel.de   
Contact: Ralf-Uwe Kuehnel, Dr.       R.Kuehnel@immanuel.de   
Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH, Klinik für Herz- und Thoraxchirurgie Recruiting
Bochum, Germany, 44789
Contact: Justus Strauch, Prof. Dr.       justus.strauch@bergmannsheil.de   
Contact: Peter-Lukas Haldenwang, PD Dr.       peter.haldenwang@bergmannsheil.de   
Universitätsklinikum Bonn, Klinik und Poliklinik für Herzchirurgie Not yet recruiting
Bonn, Germany, 53127
Contact: Miriam Silaschi, Dr.         
Contact: Hendrik Treede, Prof. Dr.       hendrik.treede@ukbonn.de   
Herzzentrum Dresden GmbH, Universitätsklinik an der TU Dresden, Klinik für Herzchirurgie Recruiting
Dresden, Germany, 01307
Contact: Jens Fassl, PD Dr.       Jens.Fassl@herzzentrum-dresden.com   
Contact: Klaus Matschke, Prof. Dr.       klaus.matschke@herzzentrum-dresden.com   
Universitätsklinikum Düsseldorf, Klinik für Kardiovaskuläre Chirurgie Recruiting
Düsseldorf, Germany, 40225
Contact: Payam Akhyari, Prof. Dr.       Payam.Akhyari@med.uni-duesseldorf.de   
Contact: Moritz B Immohr       Moritz.Immohr@med.uni-duesseldorf.de   
Mitteldeutsches Herzzentrum, Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Herzchirurgie Recruiting
Halle (Saale), Germany, 06120
Contact: Britt Hofmann, PD Dr.       britt.hofmann@uk-halle.de   
Contact: Andreas Simm, Prof. Dr.       andreas.simm@uk-halle.de   
Herzzentrum Leipzig, Universitätsklinik für Herzchirurgie Recruiting
Leipzig, Germany, 04289
Contact: Sven Lehmann, Prof. Dr.       Sven-Lehmann@helios-gesundheit.de   
Contact: Thopmas Schroeter, Dr.       thomas.schroeter@helios-gesundheit.de   
Sponsors and Collaborators
Jena University Hospital
CytoSorbents, Inc
Thermo Fisher Scientific
Fraunhofer Institute for Interfacial Engineering and Biotechnology
German Federal Ministry of Education and Research
Investigators
Layout table for investigator information
Study Director: Mahmoud Diab, Dr. Jena University Hospital, Department of Cardiac and Thoracic Surgery
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications:

Layout table for additonal information
Responsible Party: Jena University Hospital
ClinicalTrials.gov Identifier: NCT03266302    
Other Study ID Numbers: ZKSJ0108
First Posted: August 30, 2017    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jena University Hospital:
vasodilatory shock
hemoadsorption
cardiac surgery
cytokines
Additional relevant MeSH terms:
Layout table for MeSH terms
Endocarditis, Bacterial
Endocarditis
Heart Diseases
Cardiovascular Diseases
 Bacterial Infections
Cardiovascular Infections
Infection